FDA's TEMPO pilot lets AI medical devices launch pre-authorization

The FDA's new TEMPO pilot program is letting companies like Cadence and Limbic release generative AI medical devices to patients without full marketing authorization first. This means certain digital health products for mental health support could reach users faster, shifting how we think about regulation for AI tools.